Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-12-11
2007-12-11
Angell, Jon E. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S325000, C435S375000, C536S023100, C536S024300, C536S024500
Reexamination Certificate
active
11376033
ABSTRACT:
Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.
REFERENCES:
patent: 5686242 (1997-11-01), Bruice et al.
patent: 5719042 (1998-02-01), Kishimoto et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5844082 (1998-12-01), Kishimoto et al.
patent: 6110667 (2000-08-01), Lopez-Nieto et al.
patent: 6159694 (2000-12-01), Karras
patent: 6248586 (2001-06-01), Monia et al.
patent: 6514725 (2003-02-01), Kishimoto et al.
patent: 6727064 (2004-04-01), Karras
patent: 6727084 (2004-04-01), Hoyoux et al.
patent: 0 676 469 (1995-10-01), None
patent: WO 96/16175 (1996-05-01), None
patent: WO 00/61602 (2000-10-01), None
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nat. Biotechnol., 21(12), pp. 1457-1465.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Jan. 2005, Expert Opinion on Drug Delivery, vol. 2, No. 1, pp. 3-28.
Groothuis, The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery, Jan. 2000, Neuro-Oncology, 2(1), pp. 45-59.
Aberg, et al., “Selective Introduction of Antisense Oligonucleotides into Single Adult CNS Progenitor Cells Using Electroporation Demonstrates the Requirement of STAT3 Activation for CNTF-Induced Gliogenesis,”Molecular and Cellular Neuroscience, vol. 17, pp. 426-443 (2001).
Agrawal, “Antisense oligonucleotides: towards clinical trials,” TIBECH, vol. 14, pp. 376-387 (1996).
Barton, et al., “Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines,”Molecular Cancer Therapeutics, vol. 3:1, pp. 11-20 (2004).
Braasch, et al., “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,”Biochemistry, vol. 41:14, pp. 4503-4510 (2002).
Branch, “A good antisense molecule is hard to find,”TIBS, vol. 23, pp. 45-50 (1998).
Catlett-Falcone, et al., “Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells,”Immunity, vol. 10, pp. 105-115 (1999).
Epling-Burnette, et al., “Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression,”J. of Clinical Investigation, vol. 107:3, pp. 351-361 (2001).
Ernst, et al., “The Carboxyl-terminal Domains of gp130-related Cytokine Receptors are Necessary for Suppressing Embryonic Stem Cell Differentiation,”J. of Biological Chemistry, vol. 274:14, pp. 9729-9737 (1999).
Gerwitz, et al., “Facilitating oligonucleotide delivery: Helping antisense deliver on its promise,”Proc. Natl. Acad. Sci, vol. 93, pp. 3161-3163 (1996).
Grandis, et al., “Requirement of Stat3 but not Stat1 Activation for Epidermal Growth Factor Receptor—mediated Cell Growth In Vitro,”J. Clin. Invest., vol. 102:7, pp. 1385-1392 (1998).
James, “Towards gene-inhibition therapy: a review of progress and prosects in the field of antiviral antisense nucleic acids and ribozymes,”Antiviral Chemistry&Chemotherapy, vol. 2:4, pp. 191-214 (1991).
Karras, et al., “STAT3 Regulates the Growth and Immunoglobulin Production of BCL1 B Cell Lymphona through Control of Cell Cycle Progression,”Cellular Immunology, vol. 202, pp. 124-135 (2000).
Konnikova, et al., “Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells,”BMC Cancer, vol. 3:23, pp. 1-9 (2003).
Lamy, “Dysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3+ Large Granular Lymphocyte Leukemia,”Blood, vol. 92:12, pp. 4771-4777 (1998).
Lui, et al., “Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival,”Blood, vol. 102:1, pp. 344-352 (2003).
Mahboubi, et al., “Desensitization of Signaling by Oncostatin M in Human Vascular Cells Involves Cytoplasmic Tyr Residue 759 in gp130 but is Not Mediated by Either Src Homology 2 Domain-containing Tyrosine Phosphatase 2 or Suppressor of Cytokine Signaling 3*,”J. of Biological Chemistry, vol. 278:27, pp. 25014-25023 (2003).
Milner, et al., “Selecting effective antisense reagents on combinatorial oligonucleotide arrays,”Nature Biotechnology, vol. 15, pp. 537-541 (1997).
Mora, et al., “Constitutive Activation of Stat3 in Human Prostate Tumors and Cell Lines: Direct Inhibition of Stat3 Signaling Induces Apoptosis of Prostate Cancer Cells,”Cancer Research, vol. 62, pp. 6659-6666 (2002).
Niu, et al., “Gene Therapy with Dominant-negative Stat3 Suppresses Growth of the Murine Melanoma B16 Tumor in Vivo,”Cancer Research, vol. 59, pp. 5059-5063 (1999).
Niu, et al., “Constitutivie Stat3 activity up-regulates VEGF expression and tumor angiogenesis,”Oncogene, vol. 21, pp. 2000-2008 (2002).
Song, et al., “Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells,”Oncogene, vol. 22, pp. 4150-4165 (2003).
Tamm, et al., “Antisense therapy in oncology: new hope for an old idea?”The Lancet, vol. 358, pp. 489-497 (2001).
Akira, et al., “Molecular Cloning of APRF, a Novel IFN-Stimulated Gene Factor 3 p91-Related Transcription Factor Involved in the gp130-Mediated Signaling Pathway,”Cell, vol. 77, pp. 63-71 (1994).
Zhong, et al., “Stat3: A STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6,”Science, vol. 264, pp. 95-98 (1994).
STAT3 Antisense Oligonucleotide Sequence Search Results, 2007.
Matzura, et al., RNAdraw: an integrated program for RNA secondary structure calculation and analysis under 32-bit Microsoft Windows,Computer Applications in the Biosciences 12(3):247-249 (1996).
Olie, et al., “A Novel Antisense Oligonucleotide Targeting Survivin Expression Induces Apoptosis and Sensitizes Lung Cancer Cells to Chemotherapy,”Cancer Research, 60:2805-2809 (2000).
Angell Jon E.
Bowman Amy H.
Cohen Charles E.
Desai Manisha A.
ISIS Pharmaceuticals Inc.
LandOfFree
Antisense oligonucleotide modulation of STAT3 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotide modulation of STAT3 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotide modulation of STAT3 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3849200